Overview

Update
Status
Acquired by on July 27, 2015
Total Equity Funding
$161M in 4 Rounds from 14 Investors
Headquarters:
Evanston, Illinois
Description:
Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.
Founders:
Categories:
Biopharma, Therapeutics, Biotechnology
Website:
http://www.naurex.com
Social:

Company Details

Update

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.

Funding Rounds (5) - $162.11M

Update
DateAmount / RoundValuationLead InvestorInvestors
Dec, 2014$80M / Series C13
May, 2014$25M / Series C0
Dec, 2012$38M / Series B7
May, 2011$18M / Series A6
Feb, 2011$1.11M / Debt Financing0

Current Team (10)

Update

Offices/Locations (1)

Update
  • HQ

    1801 Maple Avenue

    Suite 4300

    Evanston, Illinois 60201

    United States

Past Team (1)

Update

Images (2)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos